NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain

Phase 3

Completed

Conditions: Grade I/II Ankle Sprain

Interventions: Drug: diclofenac diethylamine gel 2.32%
Drug: Placebo

First Posted Date: 2009-08-10

Last Posted Date: 2012-04-20

Lead Sponsor: Novartis

Target Recruit Count: 242

Registration Number: NCT00955513

Locations: 🇩🇪
Novartis Investigative Site, Munchen, Germany

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rivastigmine 4.6 mg/24 h (5 cm^2)
Drug: Rivastigmine 9.5 mg/24 h (10 cm^2)
Drug: Rivastigmine 13.3 mg/24 h (15 cm^2)
Drug: Placebo

First Posted Date: 2009-07-29

Last Posted Date: 2013-08-28

Lead Sponsor: Novartis

Target Recruit Count: 716

Registration Number: NCT00948766

Locations: 🇺🇸
University Neurology, Inc., Cincinnati, Ohio, United States
🇺🇸
MidAmerica Neuroscience Reseach Institute, Lenexa, Kansas, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 92 locations

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010

Phase 3

Completed

Conditions: Seasonal Influenza

Interventions: Biological: inactivated split influenza vaccine

First Posted Date: 2009-07-24

Last Posted Date: 2017-04-07

Lead Sponsor: Novartis

Target Recruit Count: 126

Registration Number: NCT00945841

Locations: 🇩🇪
Site 1, Herborn, Germany
🇩🇪
Site 3, Marburg, Germany
🇩🇪
Site 2, Giessen, Germany

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
Drug: Aliskiren/Amlodipine

First Posted Date: 2009-07-21

Last Posted Date: 2011-06-08

Lead Sponsor: Novartis

Target Recruit Count: 412

Registration Number: NCT00942994

Locations: 🇺🇸
K and S Research Services, Little Rock, Arkansas, United States
🇺🇸
Scriber Kidney Center, Seattle, Washington, United States
🇺🇸
Well Pharma Medical Research, South Miami, Florida, United States

and more 2 locations

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension

Phase 4

Completed

Conditions: Stage 2 Systolic Hypertension

Interventions: Drug: valsartan, amlodipine, HCTZ
Drug: Losartan, HCTZ followed by valsartan, amlodipine, HCTZ

First Posted Date: 2009-07-02

Last Posted Date: 2011-03-07

Lead Sponsor: Novartis

Target Recruit Count: 488

Registration Number: NCT00931710

Locations: 🇺🇸
sites in USA, East Hanover, New Jersey, United States

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo to glycopyrronium bromide
Drug: Glycopyrronium bromide
Drug: Tiotropium

First Posted Date: 2009-06-26

Last Posted Date: 2012-08-17

Lead Sponsor: Novartis

Target Recruit Count: 1066

Registration Number: NCT00929110

Locations: 🇳🇿
Novartis Investigator Site, Wellington, New Zealand
🇺🇸
Novartis Investigative site, Charlotte, North Carolina, United States
🇺🇸
Novartis Investigative Center, Crescent Springs, Kentucky, United States

and more 1 locations

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Valsartan
Drug: Placebo for Aliskiren
Drug: Placebo for Valsartan

First Posted Date: 2009-06-25

Last Posted Date: 2012-12-06

Lead Sponsor: Novartis

Target Recruit Count: 1143

Registration Number: NCT00927394

Locations: 🇺🇸
Investigative Site, Philadelphia, Pennsylvania, United States

Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion

Phase 4

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Pimecrolimus

First Posted Date: 2009-06-22

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 20

Registration Number: NCT00925730

Locations: 🇩🇪
Novartis Investigative Site, Frankfurt am Main, Germany

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Phase 2

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Canakinumab
Drug: Placebo
Drug: Metformin

First Posted Date: 2009-05-12

Last Posted Date: 2012-02-20

Lead Sponsor: Novartis

Target Recruit Count: 556

Registration Number: NCT00900146

Locations: 🇦🇷
Centro de Investigaciones Clinicas del Litoral, Santa Fe, Argentina
🇵🇪
Clinica Chiclayo, Chiclayo, Peru
🇮🇳
King George Hospital, Visakhapatnam, India

and more 85 locations

Efficacy and Safety of BGG492 in the Treatment of Migraine

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: BGG492
Drug: Sumatriptan
Drug: Placebo

First Posted Date: 2009-05-04

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis

Target Recruit Count: 75

Registration Number: NCT00892203

Locations: 🇺🇸
California Clinical Trials, 1560 Chevy Chase Drive, Suite 140, Glendale, California, United States
🇺🇸
California Clinical Trials, 15625 Lakewood Boulevard, Paramount, California, United States
🇩🇪
Novartis Investigator Site, Munich, Germany

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy